Recent study has shown that RSK inhibitors BI-D1870 and BRD7389 significantly reduced the proliferation of BRAF mutant melanoma cells that have acquired resistance to dual BRAF and MEK inhibitor treatment (Theodosakis et al., 2017). This evidence concerns the gene RPS6KA3 and melanoma.